The third quarter 2025 earnings season has largely concluded, painting a picture of corporate resilience and strategic adaptation in the face of evolving economic conditions. Overall, the S&P 500 demonstrated robust performance, with earnings growth exceeding initial projections. However, the market's reaction was nuanced, reflecting a complex interplay of
Bullish (BLSH) Q3 2025 earnings beat revenue forecasts but missed on EPS. The stock rose pre-market as investors focus on strong growth and new crypto product launches.
Bullish (NYSE: BLSH), an institutionally focused global digital asset platform that provides market infrastructure and information services, today announced financial results for the third quarter ended September 30, 2025.
Nvidia Corp. is set to release its third-quarter financials on Wednesday, November 19, and cryptocurrency bettors are increasingly confident that the artificial intelligence giant will surpass earnings expectations.
The global financial landscape is currently grappling with a significant downturn, characterized by a pervasive "risk-off" sentiment that has sent ripples across various asset classes. In a stark development, Bitcoin (BTC), the world's leading cryptocurrency, has dramatically fallen below the critical $100,000 threshold, signaling a profound shift in investor
The cryptocurrency landscape is undergoing a profound transformation as a growing number of digital asset firms shed their private status to embrace public markets. This pivotal trend, driven by a desire for increased legitimacy, capital access, and broader investor appeal, marks a significant maturation of the crypto industry. While much speculation has often surrounded Grayscale [...]
Bullish (NYSE: BLSH), an institutionally focused global digital asset platform that provides market infrastructure and information services, released its monthly metrics for October 2025 on Thursday, November 6, 2025.
Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam Therapeutics.
